Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
Recruiting now · Phase 1
Conditions studied: B-cell Acute Lymphoblastic Leukemia
In brief
This is a phase I, open label study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of allogeneic, CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells in pediatric and young adults patients with relapsed/refractory B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL).
Key facts
- Study ID
- NCT06080191
- Run by
- Bambino Gesù Hospital and Research Institute
- People needed
- 24
- Starts
- 2024-04-28
- Expected to finish
- 2041-06-01
- Last updated by the study team
- 2025-12-02
Who can join
Age: 1 and older, up to 35. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Ospedale Pediatrico Bambino Gesù — Rome, Italy, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.